الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 102 |  |  |
| | | from | 102 | | |
Abstract
Hepatitis C infection is a leading cause of morbidity and mortality with a global prevalence of approximately 3%. More than 200 million people worldwide have been infected with HCV. chronic HCV infection can lead to cirrhosis and hepatocellular carcinoma (HCC).
Chronic hepatitis C is a chronic viral infection that can be cured by antiviral therapy. Importantly, successful antiviral treatment can prevent short- and long-term complications of HCV infection.
Pegylated interferon (pegIFN) and ribavirin achieve sustained virological response in 45–50% of patients, of genotype 4 that’s prevalent in Egypt.
Sofosbuvir is a pangenotypic nucleotide inhibitor of NS5B polymerase.
One of the new regimens used is daily fixed-dose combination of Ledipasvir (90 mg)/Sofosbuvir (400 mg) for 12 weeks.
Sustained virological response (SVR), defined as an undetectable serum HCV RNA at 12 weeks (SVR12) or 24 weeks (SVR24) after treatment completion, is the parameter most often used to identify patients who have successfully cleared infection.
The present study was held to detect the SVR 12 in adolescent aged 12-18 year who received daily fixed-dose combination of Ledipasvir (90 mg)/ Sofosbuvir (400 mg) for 12 weeks.
The study was conducted on 50 adolescent patients HCV positive cases who received combination of Ledipasvir (90mg)/Sofosbuvir (400mg) in the cases were collected from outpatient clinic of Tropical Medicine Department, Alex Main University Hospital and other outpatient clinic (Rosetta and ,Idkuo hepatology clinic) from5/2017 to 7/2018, proved to be chronic hepatitis C by full investigation. The subjects were to detect SVR12 at the end of treatment and any side effects occurred.
Patients were excluded from the study e.g: those with malignancy, renal disease, autoimmune, hepatitis B virus and chronic inflammatory conditions, cytopenias and hypoalbuminemia.
All patients will be subjected to the following:
1. Detailed history taking and clinical examination.
2. Routine laboratory investigations before and after therapy:
• Complete blood picture.
• Liver function test; ALT, AST, GGT, ALP, serum bilirubin (total, direct), PT, INR, total serum protein, serum albumin.
• Alpha fetoprotein.
3. Renal function test: blood urea, creatinine level and GFR.
4. TSH, T3, T4.
5. ANA, ASMA, LKM Ab.
6. PCR was done before treatment start, at week 12(EOT) and12weeks after end of treatment (SVR12) .
7. Abdominal ultrasonography.
8. All these investigations will be repeated 4, 8, 12 weeks after treatment
9. FIb-4.